Colocation Still Matters: Conformance Quality and the Interdependence of R&D and Manufacturing in the Pharmaceutical Industry

被引:52
|
作者
Gray, John V. [1 ]
Siemsen, Enno [2 ]
Vasudeva, Gurneeta [2 ]
机构
[1] Ohio State Univ, Fisher Coll Business, Columbus, OH 43210 USA
[2] Univ Minnesota, Carlson Sch Management, Minneapolis, MN 55455 USA
关键词
colocation; knowledge interdependence; organizational design; intraorganizational learning; quality management; pharmaceutical manufacturing; information technology; INFORMATION-TECHNOLOGY; MANAGEMENT-PRACTICES; PRODUCT DEVELOPMENT; IMPACT; FIRM; PERFORMANCE; COMMUNICATION; COORDINATION; INTEGRATION; KNOWLEDGE;
D O I
10.1287/mnsc.2014.2104
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
This study investigates the conformance quality benefits of colocating manufacturing with research and development (R&D) activities. Findings from a panel data set of U.S.-based pharmaceutical plants over a 13-year period reveal that colocation of manufacturing and R&D relates to better conformance quality, on average, across the entire sample. We find that these benefits of colocation persist throughout the time period we study (1994-2007), which is surprising, given the rapid development of information and communication technologies during that time. These benefits are particularly enhanced for manufacturing plants operating with processes that involve a high level of tacit process knowledge and that belong to large firms. Our findings highlight the importance of matching organizational design with process and firm characteristics in settings involving knowledge interdependence. They also highlight the continued value of physical proximity through geographical colocation between manufacturing and R&D activities to achieve desired quality outcomes.
引用
收藏
页码:2760 / 2781
页数:22
相关论文
共 50 条
  • [21] Measuring US Pharmaceutical Industry R&D Spending
    Joseph Golec
    John Vernon
    [J]. PharmacoEconomics, 2008, 26 : 1005 - 1017
  • [22] The interdependence of R&D, innovations, and productivity: case of Polish manufacturing companies
    Yaghi, Adriana Zablocka-Abi
    Tomaszewski, Tomasz
    [J]. EKONOMIA I PRAWO-ECONOMICS AND LAW, 2024, 23 (01): : 195 - 212
  • [23] Comparison of external R&D and internal R&D: Based on the perspective of S&T development of China's pharmaceutical manufacturing industry
    Wu, Di
    Wang, Su
    Chang, Senhao
    Lian, Guiyu
    Chen, Yuwen
    [J]. PLOS ONE, 2022, 17 (06):
  • [24] Challenges faced by the pharmaceutical industry: training graduates for employment in pharmaceutical R&D
    Mooney, KG
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 12 (04) : 353 - 359
  • [25] Pharmaceutical R&D in the spotlight: why is there still unmet medical need?
    Schmid, Esther F.
    Smith, Dennis A.
    [J]. DRUG DISCOVERY TODAY, 2007, 12 (23-24) : 998 - 1006
  • [26] R&D and regional networks dynamics in Dutch pharmaceutical industry
    VanGeenhuizen, M
    VanderKnaap, B
    [J]. TIJDSCHRIFT VOOR ECONOMISCHE EN SOCIALE GEOGRAFIE, 1997, 88 (04) : 307 - 320
  • [27] Putting a new spin on R&D assets in the pharmaceutical industry
    Dewdney, JM
    Smith, RAG
    [J]. DRUG DISCOVERY TODAY, 1998, 3 (08) : 353 - 354
  • [28] Measuring the change in R&D efficiency of the Japanese pharmaceutical industry
    Hashimoto, Akihiro
    Haneda, Shoko
    [J]. RESEARCH POLICY, 2008, 37 (10) : 1829 - 1836
  • [29] Compulsory licenses in the pharmaceutical industry: Pricing and R&D strategies
    Sarmah, Archita
    De Giovanni, Domenico
    De Giovanni, Pietro
    [J]. EUROPEAN JOURNAL OF OPERATIONAL RESEARCH, 2020, 282 (03) : 1053 - 1069
  • [30] R&D INVESTMENTS, INTANGIBLE CAPITAL AND PROFITABILITY IN THE PHARMACEUTICAL INDUSTRY
    Goncharov, I
    Mahlich, J. C.
    Yurtoglu, B.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A419 - A419